Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1):e002236.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550.
   PubMed Web of Science ®Google Scholar
• Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305–317.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997.
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y. Tocilizumab can efficiently prevent bone destruction in patients with recent-onset rheumatoid arthritis. Mod Rheumatol. 2021;31(5):966–971.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–1923.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Kondo M, Shono E, et al. Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice. Mod Rheumatol. 2020;30(5):807–815.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
   PubMed Web of Science ®Google Scholar
• Katsushima M, Minamino H, Shirakashi M, et al. High plasma homocysteine level is associated with increased prevalence of non-remission state in rheumatoid arthritis: findings from the KURAMA cohort. Mod Rheumatol. 2022;2022:roac106.
   Google Scholar
• Watanabe R, Hashimoto M, Murata K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45(1):35–44.
   PubMedGoogle Scholar
• Kawashiri SY, Kawakami A, Iwamoto N, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011;21(4):365–369.
   PubMed Web of Science ®Google Scholar
• Koga T, Okada A, Fukuda T, et al. Prognostic factors toward clinically relevant radiographic progression in patients with rheumatoid arthritis in clinical practice: a Japanese multicenter, prospective longitudinal cohort study for achieving a treat-to-target strategy. Medicine. 2016;95(17):e3476.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sekiguchi M, Hirata S, et al. Predictive factors for structural remission using abatacept: results from the ABROAD study. Mod Rheumatol. 2019;29(3):406–412.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1(8646):1036–1038.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Amano K, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients–REACTION 52-week study. Rheumatology. 2011;50(10):1908–1915.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, Van Der Heijde D, Boers M, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol. 2002;29(11):2306–2312.
   PubMed Web of Science ®Google Scholar
• Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31–35.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kato M, Tanaka Y, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis. 2018;77(9):1268–1275.
   PubMed Web of Science ®Google Scholar
• Hirabayashi Y, Munakata Y, Miyata Met al. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: a multi-center, prospective cohort study by the. Mod Rheumatol. 2016;26(6):828–835.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2022;2022:annrheumdis-2022-222784.
   Google Scholar
• Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242(2):237–239.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Kang S. IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 2022;40:323–348.
   PubMed Web of Science ®Google Scholar
• Boyapati A, Schwartzman S, Msihid J, et al. Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating Sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheumatol. 2020;72(9):1456–1466.
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Hashimoto M, Watanabe R, et al. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study. Scand J Rheumatol. 2021;2021:1–10.
   Google Scholar
• Okano T, Inui K, Tada M, et al. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int. 2016;36(3):349–357.
   PubMed Web of Science ®Google Scholar
• Narvaez J, Magallares B, Diaz Torne C, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum. 2016;45(4):386–390.
   PubMed Web of Science ®Google Scholar
• Maneiro RJ, Salgado E, Carmona L, et al. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43(1):9–17.
   PubMed Web of Science ®Google Scholar
• Arad U, Elkayam O. Association of serum tocilizumab trough concentrations with clinical disease activity index scores in adult patients with rheumatoid arthritis. J Rheumatol. 2019;46(12):1577–1581.
   PubMed Web of Science ®Google Scholar
• Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020;59(12):3603–3610.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Watanabe R, Hashimoto M, et al. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients. Rheumatol Int. 2021;42(11):1983–1991.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Higuchi Y, Uchiyama Y, et al. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine. 2011;54(1):92–99.
   PubMed Web of Science ®Google Scholar
• Ogata A, Kato Y, Higa S, et al. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258–267.
   PubMed Web of Science ®Google Scholar
• Koga T, Okada A, Fukuda T, et al. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: a post hoc analysis of a nationwide cohort in Japan. PLoS One. 2017;12(5):e0175281.
   PubMed Web of Science ®Google Scholar
• van der Linden MP, Boja R, Klarenbeek NB, et al. Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. Ann Rheum Dis. 2010;69(4):727–729.
   PubMed Web of Science ®Google Scholar